We are pleased to share the data breakdown from the Cancer52 Patient Survey, conducted in summer 2024.
Cancer52 Patient Survey Data
If you use this data, please reference as ‘Cancer52 Patient Survey 2024’
Also see the analysis report by IQVIA and slide set from their presentation of the results at the Cancer52 All Member Meeting, 6th November.
Please note that to ensure confidentiality, cancer types that obtained 10 or less responses have been omitted from the breakdown. These cancer types are listed below:
22. Lymphoma: 10 responses
23. Thyroid (follicular and papillary): 9 responses
24. Skin: 5 responses
25. Testicular: 5 responses
26. Ocular Melanoma: conjunctival: 4 responses
27. Germ cell: 3 responses
28. Cancer of unknown primary: 2 responses
29. Cervical: 2 responses
30. Head and neck: 2 responses
31. Mucosal melanomas: 2 responses
32. Neuroendocrine (or Carcinoid : of any primary site inc. Merkel cell, Pheo-Paraganglioma and Medullary Thyroid): 2 responses
33. Adrenal: 1 response
34. GIST (stromal tumour): 1 response
35. Liver (hepatocellular carcinoma HCC): 1 response
36. Oesophageal: 1 response
37. Gastric (stomach): 0 responses
38. Gestational Trophoblastic Disease: 0 responses
39. Myelofibrosis: 0 responses
40. Pancreas (not Neuroendocrine): 0 responses
41. Parathyroid: 0 responses
42. Vaginal: 0 responses
43. Vulval: 0 responses
If you have any questions on the data set, please contact Sasha Daly (Sasha.Daly@Cancer52.org.uk).
Comments